March 10, 2016
March 10, 2016 - PRESSADVANTAGE -
BloodThinnerHelp.com reports on signficant parallels discovered between Xarelto and Pradaxa lawsuits, which now provide Xarelto lawsuit plaintiffs with some comfort as they look ahead to 2017 bellwether trials. Xarelto lawsuit numbers continue to increase on a regular basis. Lawsuits which have been federally filed were consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592. These cases now number over 2,800. In addition, another group of more than 600 cases have been consolidated in Philadelphia, Pennsylvania by the Court of Common Pleas to form a mass tort.
Xarelto lawsuits consolidated in the MDL are being overseen in Eastern Louisiana by the Honorable Judge Eldon Fallon. They have all similarly been filed against defendants Bayer AG and Janssen Pharmaceuticals, (a subdivision of Johnson & Johnson corporation), and all plaintiffs filing allege strikingly similar complaints regarding the potential dangers of the drug.
Xarelto is a new-generation blood thinner which was initially released to market without a corresponding antidote. The drug was approved by the U.S. Food and Drug Administration to treat patients who are recovering from knee and hip replacement surgeries, deep vein thrombosis, pulmonary embolism, or atrial fibrillation. It helps to reduce the risk of blood clot formations and strokes in these patients.
Pradaxa is a similar new-generation blood thinner. This drug, however, was marketed by Boehringer Ingelheim in October of 2010. Similarly to Xarelto, it did not take long after its initial market release for the anticoagulant to be surrounded by more than 3,500 adverse event reports. Over 750 of these FDA adverse event reports described fatalities experienced by Pradaxa patients. After only a short time, Pradaxa was the topic of more than 4,000 lawsuits, and plaintiffs involved were anxiously awaiting trial. Instead, however, the evening before the trial was set to begin, defendant Boehringer Ingelheim settled the lawsuits by agreeing to pay $650 million to affected plaintiffs.
Current Xarelto lawsuit plaintiffs look to this occurrence and find hope that their current pursuits will bring them some justice as their cases get closer to trial dates. At this time, Xarelto plaintiffs have heard no talks of settlement from Bayer or Janssen, although controversies surrounding the companies, Xarelto, and the FDA approval process of the drug continue to surge.
Attorney Joseph Osborne is now working to ensure that everyone who feels that they were negatively affected after using Xarelto will be provided the important opportunity of exploring their legal rights. He believes that other plaintiffs will be able to join the current MDL as the cases await further legal proceedings. Patients affected may be entitled to legal action and substantial compensation. In order to help those deserving pursue justice, Attorney Osborne is currently offering free legal consultations for affected parties.
To ask questions about Xarelto or request further information, please contact Attorney Joseph Osborne by calling (866) 425-8902.
###
For more information about BloodThinnerHelp.com, contact the company here:
BloodThinnerHelp.com
Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432
